Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: Implications for trial design

G. R. Pond, J. Bellmunt, J. E. Rosenberg, D. F. Bajorin, A. M. Regazzi, T. K. Choueiri, A. Q. Qu, G. Niegisch, P. Albers, A. Necchi, G. Di Lorenzo, R. Fougeray, Y. N. Wong, S. S. Sridhar, Y. J. Ko, M. I. Milowsky, M. D. Galsky, G. Sonpavde

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: Implications for trial design'. Together they form a unique fingerprint.

Medicine & Life Sciences